27,253 Shares in Emergent BioSolutions Inc. (NYSE:EBS) Acquired by PFG Investments LLC

PFG Investments LLC bought a new stake in Emergent BioSolutions Inc. (NYSE:EBS) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 27,253 shares of the biopharmaceutical company’s stock, valued at approximately $228,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. CWM LLC increased its position in Emergent BioSolutions by 32,706.7% during the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 4,906 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Emergent BioSolutions during the second quarter worth approximately $41,000. Verus Capital Partners LLC bought a new position in shares of Emergent BioSolutions in the second quarter valued at $68,000. Avidian Wealth Solutions LLC bought a new position in Emergent BioSolutions in the 1st quarter valued at about $33,000. Finally, Tidal Investments LLC purchased a new position in shares of Emergent BioSolutions during the first quarter valued at approximately $34,000. 78.40% of the stock is owned by institutional investors.

Emergent BioSolutions Stock Performance

Shares of EBS stock opened at $9.05 on Friday. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.54 and a current ratio of 1.06. Emergent BioSolutions Inc. has a fifty-two week low of $1.42 and a fifty-two week high of $15.10. The stock has a 50 day moving average price of $8.35 and a two-hundred day moving average price of $7.40. The company has a market capitalization of $478.81 million, a P/E ratio of -0.81 and a beta of 1.59.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.35). Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. The company had revenue of $254.70 million during the quarter, compared to the consensus estimate of $199.47 million. During the same period in the previous year, the company earned ($1.06) earnings per share. Analysts expect that Emergent BioSolutions Inc. will post -1.3 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have weighed in on EBS. Benchmark reissued a “buy” rating and issued a $8.00 price objective on shares of Emergent BioSolutions in a research report on Friday, August 16th. Rodman & Renshaw reissued a “buy” rating and set a $16.00 price objective on shares of Emergent BioSolutions in a report on Friday, September 13th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.